The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Leber Congenital Amaurosis (LCA) Market Research Report 2025
Synopsis
Leber congenital amaurosis is a kind of autosomal recessive genetic disease, it is the main genetic disease that brings about children blindness, accompany mental nerve symptom, wait like intellectual inferior, hearing obstacle, epilepsy, conus cornea can happen when some age is older or spherical cornea.
The global Leber Congenital Amaurosis (LCA) market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
North American market for Leber Congenital Amaurosis (LCA) is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Leber Congenital Amaurosis (LCA) is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global market for Leber Congenital Amaurosis (LCA) in Hospitals is estimated to increase from $ million in 2023 to $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global companies of Leber Congenital Amaurosis (LCA) include AmpliPhi Biosciences, Editas Medicine, Novelion Therapeutics, ProQR Therapeutics and Spark Therapeutics, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Leber Congenital Amaurosis (LCA), with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Leber Congenital Amaurosis (LCA).
Report Scope
The Leber Congenital Amaurosis (LCA) market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Leber Congenital Amaurosis (LCA) market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Leber Congenital Amaurosis (LCA) companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
AmpliPhi Biosciences
Editas Medicine
Novelion Therapeutics
ProQR Therapeutics
Spark Therapeutics
Segment by Type
Infantile Type
Juvenile Type
Segment by Application
Hospitals
Eye Clinics
Medical Research Institute
Other
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Leber Congenital Amaurosis (LCA) companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Leber congenital amaurosis is a kind of autosomal recessive genetic disease, it is the main genetic disease that brings about children blindness, accompany mental nerve symptom, wait like intellectual inferior, hearing obstacle, epilepsy, conus cornea can happen when some age is older or spherical cornea.
The global Leber Congenital Amaurosis (LCA) market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
North American market for Leber Congenital Amaurosis (LCA) is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Leber Congenital Amaurosis (LCA) is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global market for Leber Congenital Amaurosis (LCA) in Hospitals is estimated to increase from $ million in 2023 to $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global companies of Leber Congenital Amaurosis (LCA) include AmpliPhi Biosciences, Editas Medicine, Novelion Therapeutics, ProQR Therapeutics and Spark Therapeutics, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Leber Congenital Amaurosis (LCA), with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Leber Congenital Amaurosis (LCA).
Report Scope
The Leber Congenital Amaurosis (LCA) market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Leber Congenital Amaurosis (LCA) market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Leber Congenital Amaurosis (LCA) companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
AmpliPhi Biosciences
Editas Medicine
Novelion Therapeutics
ProQR Therapeutics
Spark Therapeutics
Segment by Type
Infantile Type
Juvenile Type
Segment by Application
Hospitals
Eye Clinics
Medical Research Institute
Other
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Leber Congenital Amaurosis (LCA) companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Leber Congenital Amaurosis (LCA) Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Infantile Type
1.2.3 Juvenile Type
1.3 Market by Application
1.3.1 Global Leber Congenital Amaurosis (LCA) Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Hospitals
1.3.3 Eye Clinics
1.3.4 Medical Research Institute
1.3.5 Other
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Leber Congenital Amaurosis (LCA) Market Perspective (2019-2030)
2.2 Leber Congenital Amaurosis (LCA) Growth Trends by Region
2.2.1 Global Leber Congenital Amaurosis (LCA) Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Leber Congenital Amaurosis (LCA) Historic Market Size by Region (2019-2024)
2.2.3 Leber Congenital Amaurosis (LCA) Forecasted Market Size by Region (2025-2030)
2.3 Leber Congenital Amaurosis (LCA) Market Dynamics
2.3.1 Leber Congenital Amaurosis (LCA) Industry Trends
2.3.2 Leber Congenital Amaurosis (LCA) Market Drivers
2.3.3 Leber Congenital Amaurosis (LCA) Market Challenges
2.3.4 Leber Congenital Amaurosis (LCA) Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Leber Congenital Amaurosis (LCA) Players by Revenue
3.1.1 Global Top Leber Congenital Amaurosis (LCA) Players by Revenue (2019-2024)
3.1.2 Global Leber Congenital Amaurosis (LCA) Revenue Market Share by Players (2019-2024)
3.2 Global Leber Congenital Amaurosis (LCA) Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Leber Congenital Amaurosis (LCA) Revenue
3.4 Global Leber Congenital Amaurosis (LCA) Market Concentration Ratio
3.4.1 Global Leber Congenital Amaurosis (LCA) Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Leber Congenital Amaurosis (LCA) Revenue in 2023
3.5 Leber Congenital Amaurosis (LCA) Key Players Head office and Area Served
3.6 Key Players Leber Congenital Amaurosis (LCA) Product Solution and Service
3.7 Date of Enter into Leber Congenital Amaurosis (LCA) Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Leber Congenital Amaurosis (LCA) Breakdown Data by Type
4.1 Global Leber Congenital Amaurosis (LCA) Historic Market Size by Type (2019-2024)
4.2 Global Leber Congenital Amaurosis (LCA) Forecasted Market Size by Type (2025-2030)
5 Leber Congenital Amaurosis (LCA) Breakdown Data by Application
5.1 Global Leber Congenital Amaurosis (LCA) Historic Market Size by Application (2019-2024)
5.2 Global Leber Congenital Amaurosis (LCA) Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Leber Congenital Amaurosis (LCA) Market Size (2019-2030)
6.2 North America Leber Congenital Amaurosis (LCA) Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Leber Congenital Amaurosis (LCA) Market Size by Country (2019-2024)
6.4 North America Leber Congenital Amaurosis (LCA) Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Leber Congenital Amaurosis (LCA) Market Size (2019-2030)
7.2 Europe Leber Congenital Amaurosis (LCA) Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Leber Congenital Amaurosis (LCA) Market Size by Country (2019-2024)
7.4 Europe Leber Congenital Amaurosis (LCA) Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Leber Congenital Amaurosis (LCA) Market Size (2019-2030)
8.2 Asia-Pacific Leber Congenital Amaurosis (LCA) Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Leber Congenital Amaurosis (LCA) Market Size by Region (2019-2024)
8.4 Asia-Pacific Leber Congenital Amaurosis (LCA) Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Leber Congenital Amaurosis (LCA) Market Size (2019-2030)
9.2 Latin America Leber Congenital Amaurosis (LCA) Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Leber Congenital Amaurosis (LCA) Market Size by Country (2019-2024)
9.4 Latin America Leber Congenital Amaurosis (LCA) Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Leber Congenital Amaurosis (LCA) Market Size (2019-2030)
10.2 Middle East & Africa Leber Congenital Amaurosis (LCA) Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Leber Congenital Amaurosis (LCA) Market Size by Country (2019-2024)
10.4 Middle East & Africa Leber Congenital Amaurosis (LCA) Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 AmpliPhi Biosciences
11.1.1 AmpliPhi Biosciences Company Detail
11.1.2 AmpliPhi Biosciences Business Overview
11.1.3 AmpliPhi Biosciences Leber Congenital Amaurosis (LCA) Introduction
11.1.4 AmpliPhi Biosciences Revenue in Leber Congenital Amaurosis (LCA) Business (2019-2024)
11.1.5 AmpliPhi Biosciences Recent Development
11.2 Editas Medicine
11.2.1 Editas Medicine Company Detail
11.2.2 Editas Medicine Business Overview
11.2.3 Editas Medicine Leber Congenital Amaurosis (LCA) Introduction
11.2.4 Editas Medicine Revenue in Leber Congenital Amaurosis (LCA) Business (2019-2024)
11.2.5 Editas Medicine Recent Development
11.3 Novelion Therapeutics
11.3.1 Novelion Therapeutics Company Detail
11.3.2 Novelion Therapeutics Business Overview
11.3.3 Novelion Therapeutics Leber Congenital Amaurosis (LCA) Introduction
11.3.4 Novelion Therapeutics Revenue in Leber Congenital Amaurosis (LCA) Business (2019-2024)
11.3.5 Novelion Therapeutics Recent Development
11.4 ProQR Therapeutics
11.4.1 ProQR Therapeutics Company Detail
11.4.2 ProQR Therapeutics Business Overview
11.4.3 ProQR Therapeutics Leber Congenital Amaurosis (LCA) Introduction
11.4.4 ProQR Therapeutics Revenue in Leber Congenital Amaurosis (LCA) Business (2019-2024)
11.4.5 ProQR Therapeutics Recent Development
11.5 Spark Therapeutics
11.5.1 Spark Therapeutics Company Detail
11.5.2 Spark Therapeutics Business Overview
11.5.3 Spark Therapeutics Leber Congenital Amaurosis (LCA) Introduction
11.5.4 Spark Therapeutics Revenue in Leber Congenital Amaurosis (LCA) Business (2019-2024)
11.5.5 Spark Therapeutics Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
